2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
In 2023 there are still even 75% of patients over the target of low-density lipoprotein cholesterol (LDL-C), and hypercholesterolemia is the most common and the worst monitored cardiovascular risk factor. How it is possible, considering the knowledge we have on the role of cholesterol in the process...
Main Authors: | Maciej Banach, Stanisław Surma, Peter P. Toth |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2023-11-01
|
Series: | Archives of Medical Science |
Subjects: | |
Online Access: | https://www.archivesofmedicalscience.com/2023-The-year-in-cardiovascular-disease-the-year-of-new-and-prospective-lipid-lowering,174743,0,2.html |
Similar Items
-
Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
by: Maciej Banach, et al.
Published: (2022-11-01) -
Cholesterol-Lowering Strategies for Cardiovascular Disease Prevention: The Importance of Intensive Treatment and the Simplification of Medical Therapy
by: Vincenzo Sucato, et al.
Published: (2024-03-01) -
Exploring Contemporary Data on Lipid-Lowering Therapy Prescribing in Patients Following Discharge for Atherosclerotic Cardiovascular Disease in the South of Italy
by: Anna Citarella, et al.
Published: (2022-07-01) -
Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association
by: Maciej Banach, et al.
Published: (2023-11-01) -
Evaluation of the polypill therapy effectiveness in patients with arterial hypertension and dyslipidemia who underwent COVID-19
by: V.E. Oleynikov, et al.
Published: (2024-03-01)